BCM
FHTX icon

Bridgeway Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Bridgeway Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357K Hold
74,600
– – 0.01% 892
2025
Q4 		$403K Hold
74,600
– – 0.01% 866
2025
Q3 		$365K Buy
74,600
+10,500
+16% +$55.7K 0.01% 871
2025
Q2 		$301K Buy
64,100
+25,000
+64% +$104K 0.01% 862
2025
Q1 		$143K Buy
39,100
+5,600
+17% +$25.5K ﹤0.01% 985
2024
Q4 		$158K Sell
33,500
-25,000
-43% -$182K ﹤0.01% 1051
2024
Q3 		$545K Buy
58,500
+1,000
+2% +$7.24K 0.01% 842
2024
Q2 		$331K Buy
+57,500
New +$342K 0.01% 952

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Bridgeway Capital Management's FHTX Position: Q1 2026 in Review

Bridgeway Capital Management held its Foghorn Therapeutics (FHTX) position steady in Q1 2026 at 74,600 shares worth $357K. The position accounts for 0.01% of the portfolio, ranked #892.

Bridgeway Capital Management first reported a position in FHTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $545K in Q3 2024. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Bridgeway Capital Management held 74,600 shares of Foghorn Therapeutics worth $357K as of Q1 2026.
  • Bridgeway Capital Management left its Foghorn Therapeutics share count unchanged in Q1 2026.
  • Foghorn Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #892 holding.
  • Bridgeway Capital Management first reported a position in Foghorn Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Bridgeway Capital Management's Foghorn Therapeutics position peaked at $545K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.